Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis

Inclusion Criteria: * Age between 21 and above * Patients who are diagnosed with anterior uveitis or endotheliitis with a positive aqueous real time PCR (RT-PCR) and/or positive tetraplex PCR for Cytomegalovirus (CMV) * Patients with relapses and recurrent anterior segment disease that is PCR positive for CMV in aqueous * Have not been on VIRGAN or any other form of ganciclovir therapy for the past 1 month * Consent to undergo anterior chamber tap and give aqueous and tear samples for the study * Able to undergo relevant tests (corneal pachymetry and laser flare cell photometry) * Able to come for subsequent follow-up visits Exclusion Criteria: * CMV anterior uveitis with associated retinitis * Other causes of hypertensive anterior uveitis / endotheliitis such as HSV, VZV infection * Patients who have been on any form of (topical, local or systemic) ganciclovir therapy for the past1 month. * Patients who are allergic to ganciclovir * Patients who will require systemic or intra-vitreal ganciclovir therapy * Immunocompromised patients * Positive for HIV, Hep B and Hep C * Not keen on participating in the study * Patients who are incapable, either by law or mental state, of giving consents in their own right. * Patients who are either unable or unwilling to keep scheduled appointments and adhere to the other aspects of the protocol * Patients who are pregnant or breastfeeding * Any other specified reason as determined by the clinical investigator.